Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SVRA Stock Forecast 2025-2026
$3.18
Current Price
$564.51M
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to SVRA Price Targets
+403.1%
To High Target of $16.00
+175.2%
To Median Target of $8.75
-5.7%
To Low Target of $3.00
SVRA Price Momentum
+4.3%
1 Week Change
+9.3%
1 Month Change
-27.9%
1 Year Change
+3.6%
Year-to-Date Change
-40.1%
From 52W High of $5.31
+41.0%
From 52W Low of $2.26
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Savara (SVRA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SVRA and similar high-potential opportunities.
Latest SVRA Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, SVRA has a bullish consensus with a median price target of $8.75 (ranging from $3.00 to $16.00). Currently trading at $3.18, the median forecast implies a 175.2% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 403.1% upside. Conversely, the most conservative target is provided by Andrew Fein at HC Wainwright & Co., suggesting a 5.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SVRA Analyst Ratings
7
Buy
1
Hold
0
Sell
SVRA Price Target Range
Low
$3.00
Average
$8.75
High
$16.00
Current: $3.18
Latest SVRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SVRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 28, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $6.00 |
| Dec 20, 2024 | Wells Fargo | Tiago Fauth | Overweight | Initiates | $8.00 |
| Dec 19, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $9.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $6.00 |
| Nov 13, 2024 | Evercore ISI Group | Liisa Bayko | In-Line | Downgrade | $5.00 |
| Oct 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $10.00 |
| Oct 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $10.00 |
| Oct 1, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $9.00 |
| Sep 9, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $9.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $10.00 |
| Aug 13, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $9.00 |
| Jun 27, 2024 | Guggenheim | Daniel Krizay | Buy | Maintains | $10.00 |
| Jun 27, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $10.00 |
| Jun 26, 2024 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $15.00 |
| May 21, 2024 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $11.00 |
| May 16, 2024 | Evercore ISI Group | Outperform | Maintains | $7.00 | |
| May 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $6.00 |
| May 6, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $8.00 |
| Apr 19, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $8.00 |
| Apr 18, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $8.00 |
Savara Inc. (SVRA) Competitors
The following stocks are similar to Savara based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Savara Inc. (SVRA) Financial Data
Savara Inc. has a market capitalization of $564.51M with a P/E ratio of -6.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -61.5%.
Valuation Metrics
Market Cap
$564.51M
Enterprise Value
$499.38M
P/E Ratio
-6.6x
PEG Ratio
-7.4x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+29.4%
Current Ratio
13.7x
Debt/Equity
15.7x
ROE
-61.5%
ROA
-32.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Savara Inc. (SVRA) Business Model
About Savara Inc.
What They Do
Develops therapies for rare respiratory diseases.
Business Model
Savara Inc. operates as a biopharmaceutical company focused on creating and commercializing inhalation therapies for rare and chronic respiratory diseases. The company generates revenue through the development and sale of innovative treatment options, specifically targeting conditions like pulmonary alveolar proteinosis and cystic fibrosis, which have limited existing therapies.
Additional Information
Savara Inc. is committed to addressing unmet medical needs in the healthcare sector and emphasizes safety and efficacy in its treatments. By concentrating on rare diseases, it occupies a unique niche in the biopharmaceutical market, playing a vital role in advancing respiratory health care and improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
59
CEO
Mr. Matthew Pauls J.D., M.B.A.
Country
United States
IPO Year
2017
Website
www.savarapharma.comSavara Inc. (SVRA) Latest News & Analysis
Latest News
Quick Summary
Savara, Inc. is developing MOLBREEVI for autoimmune pulmonary alveolar proteinosis (aPAP), supported by strong clinical data and multiple FDA designations, indicating a promising investment opportunity.
Why It Matters
Savara's focus on MOLBREEVI, backed by strong clinical data and FDA designations, presents a significant opportunity in the aPAP market, potentially driving stock value and investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Savara Announces New Employment Inducement Grant
17 days ago
Quick Summary
Savara Inc. granted inducement awards for options to purchase 107,000 shares of common stock to seven new employees, as announced on April 9, 2025.
Why It Matters
Savara Inc.'s grant of stock options to new employees signals confidence in growth and retention, potentially boosting performance and shareholder value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Savara Inc. will present top-line data from its Phase 3 IMPALA-2 trial of molgramostim for aPAP at two upcoming respiratory conferences in April 2024.
Why It Matters
Savara Inc.'s presentation of pivotal trial data for molgramostim could influence stock performance, signaling potential advancements in treatment for aPAP and attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
1 month ago
Quick Summary
Savara Inc. reported its Q4 and full-year financial results for 2024, highlighting the submission of a Biologics License Application (BLA) to address aPAP, a rare lung disease.
Why It Matters
Savara Inc.'s BLA submission for aPAP could lead to market approval, impacting future revenue potential and stock performance, especially given the unmet medical need in the respiratory disease sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Savara Inc. (Nasdaq: SVRA) has submitted a Biologics License Application (BLA) to the FDA for MOLBREEVI, aimed at treating aPAP, marking a significant milestone for the company.
Why It Matters
Savara's submission of the BLA for MOLBREEVI could lead to FDA approval, potentially boosting the company's stock value and market position in rare respiratory treatments.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Savara Inc. has secured a loan agreement with Hercules Capital for up to $200 million, enhancing its balance sheet post-BLA submission for MOLBREEVI to the FDA.
Why It Matters
Savara's $200 million loan enhances its financial stability and supports its FDA application for MOLBREEVI, potentially boosting future revenue and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SVRA Stock
What is Savara Inc.'s (SVRA) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Savara Inc. (SVRA) has a median price target of $8.75. The highest price target is $16.00 and the lowest is $3.00.
Is SVRA stock a good investment in 2025?
According to current analyst ratings, SVRA has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SVRA stock?
Wall Street analysts predict SVRA stock could reach $8.75 in the next 12 months. This represents a 175.2% increase from the current price of $3.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Savara Inc.'s business model?
Savara Inc. operates as a biopharmaceutical company focused on creating and commercializing inhalation therapies for rare and chronic respiratory diseases. The company generates revenue through the development and sale of innovative treatment options, specifically targeting conditions like pulmonary alveolar proteinosis and cystic fibrosis, which have limited existing therapies.
What is the highest forecasted price for SVRA Savara Inc.?
The highest price target for SVRA is $16.00 from Yasmeen Rahimi at Piper Sandler, which represents a 403.1% increase from the current price of $3.18.
What is the lowest forecasted price for SVRA Savara Inc.?
The lowest price target for SVRA is $3.00 from Andrew Fein at HC Wainwright & Co., which represents a -5.7% decrease from the current price of $3.18.
What is the overall SVRA consensus from analysts for Savara Inc.?
The overall analyst consensus for SVRA is bullish. Out of 10 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $8.75.
How accurate are SVRA stock price projections?
Stock price projections, including those for Savara Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 9:35 PM UTC